FRAMINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today released its 2023 sustainability report. The second annual report showcases Definitive Healthcare’s ongoing commitment to operating ethically, responsibly, and sustainably through the implementation and management of environmental, social, and governance (ESG) practices.
“We are firm believers in achieving our mission sustainably. We see it as both essential to our long-term success and a responsibility to the world we share,” said Jason Krantz, founder, executive chairman, and interim CEO of Definitive Healthcare. “As we grow, we’ll continue to find ways to reduce our impact on the environment and give back to communities where we live and operate.”
In the report, Definitive Healthcare highlighted the most important sustainability topics to its business, stakeholders, and growth, including the recruitment and management of a global, diverse, and inclusive workforce, privacy and data protection, and energy and emissions.
Some of Definitive Healthcare’s 2023 ESG achievements highlighted in the report include:
Environmental
Social
Governance
To learn more about Definitive Healthcare’s commitment to sustainability, please download the Sustainability Report.
About Definitive Healthcare
At Definitive Healthcare, our mission is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.
Media Contact:
Bethany Swackhamer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Brian Denyeau
ICR for Definitive Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
646-277-1251
Last Trade: | US$4.19 |
Daily Change: | 0.02 0.36 |
Daily Volume: | 432,704 |
Market Cap: | US$449.220M |
February 27, 2025 February 25, 2025 November 07, 2024 October 10, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load